Aker BioMarine

Aker BioMarine reported a 5% revenue increase in the second quarter to USD 57.90m, missing the consensus estimate of USD 60m. Adjusted EBITDA fell 4% to USD 12.90m, below analysts’ estimate of USD 14m. The result was driven by 17% revenue growth in the Human Health Ingredients segment, while the Consumer Health Products segment was weighed down by weaker US retail sales and marketing repositioning. The company continues to expect annual growth and improved profits in the Human Health Ingredients business and is reviewing strategic alternatives with a targeted transaction in 2026. » More on de.investing.com

Aker BioMarine reports a 15% rise in Q3 2025 revenue to USD 56.8m and adjusted EBITDA of USD 12.2m; the stock fell about 2.8% after the results. The Human Health Ingredients segment was the main driver with USD 30.2m in revenue (+23%) and strong EBITDA margins, while Consumer Health Products saw revenue decline 6% to USD 27.4m. The emerging business remained small and slightly operationally negative. The company confirms a new underlying cost structure of USD 12–14m, expects continued growth in HHI and aims for cash break-even in the emerging businesses; net debt stands at USD 165m (NIBD/Adjusted EBITDA 4.0x). » More on de.investing.com

Aker BioMarine reported a net profit of US$0.3 million for Q3 2025, significantly beating the earnings-per-share forecast, while revenue of US$55.3 million missed expectations of US$58.5 million. Adjusted EBITDA rose 41% to US$13.6 million and gross margin improved to 44%. Growth was driven mainly by the Human Health Ingredients and Consumer Health Products segments; the stock fell 2.81% in pre-market trading. Management expects continued growth in core segments and a stable EBITDA run rate of US$54–56 million. » More on de.investing.com